【摘 要】
：
Background and Aims: The immune system plays vital roles in hepatocellular carcinoma (HCC) initiation and pro-gression. The present study aimed to construct an immune-gene related prognostic signature (IRPS) for predicting the prognosis of HCC patients. M
【机 构】
：
Department of Traditional Chinese Medicine,The First Affiliated Hospital of Xi’an Jiaotong Universit
论文部分内容阅读
Background and Aims: The immune system plays vital roles in hepatocellular carcinoma (HCC) initiation and pro-gression. The present study aimed to construct an immune-gene related prognostic signature (IRPS) for predicting the prognosis of HCC patients. Methods: Gene expression data were retrieved from The Cancer Genome Atlas database. The IRPS was established via least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analysis. The prognostic values of the IRPS were further validated using the International Cancer Genome Consor-tium (ICGC) dataset. Results: A total of 62 genes were identified as candidate immune-related prognostic genes. According to the results of Lasso and multivariate Cox re-gression analysis, we established an IRPS and confirmed its stability and reliability in the ICGC dataset. The IRPS was significantly associated with advanced clinicopathological characteristics. Both Cox regression analyses revealed that the IRPS could be independent risk factors influencing prog-nosis of HCC patients. The relationships between the IRPS and infiltration of immune cells demonstrated that the IRPS was associated with immune cell infiltration. Furthermore, a nomogram was constructed to estimate the survival proba-bility of HCC patients. Conclusions: The IRPS was effective for predicting prognosis of HCC patients, which might serve as novel prognostic and therapeutic biomarkers for HCC.
其他文献
目的:评估venetoclax联合去甲基化药物治疗复发/难治性急性髓系白血病(AML)患者的疗效、不良反应及预后情况.方法:回顾性分析2018年7月-2020年12月接受venetoclax联合去甲基化药物的22例复发/难治性AML患者的临床资料.结果:中位随访时间9.86(95％CI 7.58～12.14)个月,19例患者获得最佳客观应答,其中7例达完全缓解,6例达骨髓完全缓解伴不完全血液学恢复,6例达部分缓解,3例患者对venetoclax联合治疗无反应.发生Ⅲ～Ⅳ级血小板计数下降、白细胞减少的患者分
纯红细胞再生障碍性贫血(pure red cell apla-sia,PRCA)是异基因造血干细胞移植少见的并发症之一,主要发生在ABO血型不合的供受者之间[1],其特征为正细胞正色素性贫血、网织红细胞减低和骨髓中红系细胞显著减低或缺如[2].rn1 病例资料rn患者,女,36岁,2017年5月确诊急性髓系白血病,予以阿糖胞苷十柔红霉素化疗3个疗程达完全缓解.2018年2月行半相合外周血干细胞移植,供者为其女儿,血型不合(A+供O+).
目的:探讨1q21扩增(简称1q)对于初治多发性骨髓瘤(NDMM)预后的影响.方法:回顾性分析2014年1月-2020年8月在徐州医科大学附属医院行FISH检测并规范治疗的171例NDMM患者的临床资料,比较伴1q与不伴1q的NDMM患者间的临床特征及生存差异,分析1q对于硼替佐米疗效的影响,探讨NDMM预后的高危因素,研究1q单独存在及与其他高危因素共存对于NDMM预后的影响.结果:①171例NDMM患者中,1q的发生率为45.6％(78/171).与非1q组比较,1q组P53缺失、IgH重排、del(
To the editor,rnWe have read the article titled “Characteristics and Out-come of Exertional Heatstroke Patients Complicated by Acute Hepatic Injury: A Cohort Study” by Ji et al.1 We con-gratulate the authors for this insightful article. In this letter, we
骨髓增生异常综合征/骨髓增殖性肿瘤(myel-odysplastic/myeloproliferative neoplasms,MDS/MPN)是一组兼具骨髓增生异常综合征(MDS)和骨髓增殖性肿瘤(MPN)特征的罕见的血液系统恶性肿瘤,具有向急性髓系白血病(AML)转化的风险.根据2016年世界卫生组织(WHO)修订的MDS/MPN分类,主要包括以下5个亚型:慢性粒单核细胞白血病(CMML),不典型慢性髓系白血病(aCML),幼年型粒单核细胞白血病(JMML),骨髓增生异常综合征/骨髓增殖性肿瘤伴环形铁
目的:探讨CEBPA基因突变与急性髓系白血病(AML)临床特征及预后的关系.方法:收集2018年1月1日-2020年1月1日初次就诊于我院的154例AML患者(排除M3型)的详细信息,其中CEBPA双突变(CEBPAdm)23例,CEBPA单突变(CEBPAsm)8例,CEBPA突变阴性(CEBPA-)123例.对AML患者的临床特征及预后进行回顾性分析,比较3组患者间完全缓解(CR)率、总生存期(OS)和无进展生存时间(PFS).结果:与CEBPA-组比较,CEBPAdm组初诊年龄小(P=0.002),
单克隆B淋巴细胞增多症(monoclonal B-cell lymphocytosis,MBL)是指健康个体外周血存在低水平的单克隆B淋巴细胞.自90年代初MBL在人群中首次发现,距今近30年的时间里,针对MBL的生物学机制的研究已取得了阶段性进展.MBL是一个存在高度异质性的庞大群体,但迄今为止,针对MBL人群的管理尚无明确的国际共识和指南可循.本文就MBL的诊断及分型、流行病学特点、分子遗传学机制及该人群的管理进行综述.
Background and Aims: Nonalcoholic fatty liver disease (NAFLD) is associated with metabolic disorders. This study aimed to explore the role of metabolic disorders in screen-ing advanced fibrosis in NAFLD patients. Methods: A total of 246 histologically-pro
A panel of experts from 22 countries recently proposed a name change from nonalcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease, or MAFLD.1 Sub-sequently, new criteria for diagnosing MAFLD were provided to help guide clinici
To the editor,rnThere remains a huge unmet need for treatment of cir-rhotic ascites. In this letter, we propose that the sodium-glucose cotransporter-2 (SGLT2) inhibitor may be a promis-ing complement for current therapy.